In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.
On 10% oleic acid-albumin-dextrose-catalase-enriched 7H11 agar medium, the MIC at which 90% of the isolates are inhibited for 20 strains of Mycobacterium tuberculosis was 0.5 microg of sparfloxacin (SPFX) or moxifloxacin (MXFX) per ml and 1.0 microg of clinafloxacin (CNFX) per ml, indicating that the in vitro activities of SPFX and MXFX were virtually identical and were slightly greater than that of CNFX. However, the in vivo activities of these drugs in a murine tuberculosis model differed considerably. Female Swiss mice were infected intravenously with 6.2 x 10(6) CFU of the H37Rv strain and treated for 4 weeks, beginning the next day after infection, with isoniazid (INH) serving as the positive control. By the criteria of 30-day survival rate, spleen weight, gross lung lesion, and mean number of CFU in the spleen, treatment with CNFX at up to 100 mg/kg of body weight six times weekly displayed no measurable effect against M. tuberculosis, whereas both SPFX and MXFX were effective; administration six times weekly of either of the latter two drugs demonstrated dosage-dependent bactericidal effects, as measured by enumeration of CFU in the spleens, and MXFX appeared more bactericidal than the same dosage of SPFX. Of the three fluoroquinolones, only MXFX at 100 mg/kg six times weekly appeared as bactericidal as INH at 25 mg/kg six times weekly. Thus, MXFX may be an important component of the newer combined regimens for treatment of tuberculosis.
Bactériologie et Hygiène, Faculté de Médecine Pitié-Salpêtrière, Paris, France.
B
B
Ji
N
N
Lounis
C
C
Maslo
C
C
Truffot-Pernot
P
P
Bonnafous
J
J
Grosset
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001372:Aza Compounds; D015169:Colony Count, Microbial; D005260:Female; D024841:Fluoroquinolones; D008168:Lung / Q000473:pathology; D051379:Mice; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D009929:Organ Size / Q000187:drug effects; D011804:Quinolines; D015363:Quinolones / Q000494:pharmacology* / Q000627:therapeutic use; D013154:Spleen / Q000187:drug effects / Q000382:microbiology / Q000473:pathology; D014376:Tuberculosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology
D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D015363:Quinolones; D000077266:Moxifloxacin